Or. Admin. R. 415-020-0005 - Definitions

Current through Register Vol. 61, No. 4, April 1, 2022

(1) "Accreditation" means the process of review and acceptance by an accreditation body.
(2) "Accreditation Body" means an organization that has been approved by the Substance Abuse and Mental Health Services Administration (SAMHSA) to accredit opioid treatment programs that use opioid agonist treatment medications.
(3) "Assessment" means the process of obtaining all pertinent biopsychosocial information, through a face-to-face interview and additional information as provided by the individual, family and collateral sources as relevant, to determine a diagnosis and to plan individualized services and supports.
(4) "Certificate" means the document or documents issued by the Division, which identifies and declares certification of a provider pursuant to OAR 309-008-0100 to 309-008-1600. A letter accompanying issuance of the certificate will detail the scope and approved service delivery locations of the certificate.
(5) "Community Mental Health Program (CMHP)" means the organization of various services for individuals with a mental health diagnosis or addictive disorders operated by or contractually affiliated with a local mental health authority and operated in a specific geographic area of the state under an agreement with the Division pursuant to OAR chapter 309, division 014.
(6) "Comprehensive maintenance treatment" means opioid agonist medication treatment that includes a broad range of clinically appropriate medical and rehabilitative services.
(7) "Diversion Control Plan" means a plan implemented by the opioid treatment program that contains specific measures to reduce the possibility of diversion of controlled substances from legitimate treatment use.
(8) "Division" means the Health Systems Division of the Oregon Health Authority (OHA).
(9) "Employee" means an individual who provides a program service or who takes part in a program service and who receives wages, a salary, or is otherwise paid by the program for providing the service.
(10) "Federal Protocols" means the standards established by the United States Secretary of Health and Human Services that determines whether an opioid treatment program is qualified to engage in opioid treatment.
(11) "Interim Maintenance Treatment" means treatment provided in conjunction with appropriate medical services while a patient is awaiting transfer to a program that provides comprehensive maintenance treatment.
(12) "Maintenance Treatment" means the administration of an opioid agonist treatment medication at stable dosage levels for a period longer than 21 days.
(13) "Medical Director" means a physician licensed to practice medicine in the State of Oregon who is designated by the opioid treatment program to be responsible for the program's medical services.
(14) "Medically Supervised Withdrawal" means the administration of an opioid agonist treatment medication in decreasing doses to an individual to alleviate adverse physical or psychological effects incident to withdrawal from the continuous or sustained use of an opioid drug and as a method of bringing the individual to a drug free state.
(15) "Medically Supervised Withdrawal Treatment" means treatment for a period of more than 30 days but not exceeding 180 days.
(16) "Medical Professional" means a medical or osteopathic physician, physician's assistant licensed by the Board of Medical Examiners, or a registered nurse or nurse practitioner licensed by the Board of Nursing.
(17) "Opiate Addiction" means a cluster of cognitive, behavioral, and physiological symptoms in which the individual continues use of opiates despite significant opiate-induced problems. Opiate addiction is characterized by repeated self-administration that usually results in tolerance, withdrawal symptoms, and compulsive drug taking.
(18) "Opioid Agonist Medication" means any drug that is approved by the Food and Drug Administration under Section 505 of Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for use in the treatment of opiate addiction.
(19) "Opioid Treatment Program" means a program that dispenses and administers opioid agonist medications in conjunction with appropriate counseling, supportive, and medical services.
(20) "Patient" means any individual who receives services in an opioid treatment program.
(21) "Patient Record" means the official legal written file for each patient, containing all the information required to demonstrate compliance with these rules. Information in program records maintained in electronic format must be able to be produced in a printed form, authenticated by signature, whether physical or digital, and date of the person who provided the service, and placed in the patient record.
(22) "Program Staff" means:
(a) An employee or person who, by contract with the program, provides a clinical service and who has the credentials required in these rules to provide the clinical service; and
(b) Any other employee of the program.
(23) "Quality Assurance" means the process of objectively and systematically monitoring and evaluating the appropriateness of patient care to identify and resolve identified problems.
(24) "Rehabilitation" means those services, such as vocational rehabilitation or academic education, which assist in overcoming the problems associated with drug abuse or drug dependence and which enable the patient to function at his or her highest potential.
(25) "State Opioid Treatment Authority" means the State Opioid Treatment Authority designated pursuant to section 409 of Public Law 92-255, the Drug Abuse Office and Treatment Act of 1972, or in lieu thereof, any other State authority designated by the Governor for purposes of exercising the authority under this section. The State Opioid Treatment Authority for Oregon is the Oregon Health Authority designee to serve in that role.
(26) "Treatment" means the specific medical and non-medical therapeutic techniques employed to assist the patient in recovering from drug abuse or drug dependence.
(27) "Urinalysis Test" or "Urinalysis" means an analytical procedure to identify the presence or absence of specific drugs or metabolites in a urine specimen.
(28) "Volunteer" means an individual who provides a program service or who takes part in a program service and who is not an employee of the program and is not paid for services. The services must be non-clinical unless the individual has the required credentials to provide a clinical service.

Notes

Or. Admin. R. 415-020-0005
HR 4-1988, f. & cert. ef. 5-10-88; HR 17-1993, f. & cert. ef. 7-23-93, Renumbered from 410-006-0005; ADAP 3-1995, f. 12-1-95, cert. ef. 3-1-96; ADS 1-2003, f. 6-13-03, cert. ef. 7-1-03; ADS 2-2008, f. & cert. ef. 11-13-08; ADS 5-2013, f. & cert. ef. 6-7-13; ADS 6-2016(Temp), f. & cert. ef. 8-10-16 thru 2-5-17; ADS 9-2016, f. & cert. ef. 12/14/2016; ADS 2-2021, temporary amend filed 09/21/2021, effective 10/01/2021 through 03/29/2022; ADS 3-2021, temporary amend filed 09/29/2021, effective 10/1/2021 through 3/29/2022; ADS 1-2022, amend filed 03/25/2022, effective 3/28/2022

Statutory/Other Authority: ORS 430.256

Statutes/Other Implemented: ORS 430.010(4)(b) & 430.560 - 430.590

The following state regulations pages link to this page.



State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.